Shire plc: Core Portfolio of Products Delivers 20% Sa... (both recurring andnon-recurring that Shi...)

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

Date:8/5/2009

both recurring and non-recurring, that Shire's management believes are not related to the core performance of Shire's business. A list of these items can be found on pages 26-27.

PRODUCT LAUNCHES

Subject to obtaining the relevant regulatory/governmental approvals, product launches planned over the next two years include:

    - MEZAVANT for the treatment of ulcerative colitis; launches will
      continue in certain EU and RoW countries in 2009 and 2010;

    - FIRAZYR for the symptomatic treatment of acute attacks of HAE; launches
      will continue in certain European and Latin American countries during
      2009 and 2010;

    - INTUNIV for the treatment of ADHD in children and adolescents in the
      US in the fourth quarter of 2009;

    - EQUASYM(R) for the treatment of ADHD; launches will continue in certain
      EU countries during 2009 and 2010;

    - DAYTRANA(R) for the treatment of ADHD in adolescents in the US in 2010;

    - Velaglucerase alfa for the treatment of Gaucher disease in the US and
      the EU in 2010; and

    - VYVANSE for the treatment of ADHD, in ex-US and ex-EU regions starting
      in 2010, and in the EU in 2011.

DIVIDEND

In respect of the six months ended June 30, 2009, the Board resolved to pay an interim dividend of 2.147 US cents per ordinary share (2008: 2.147 US cents per share).

Dividend payments will be made in Pounds Sterling to Ordinary shareholders and in US Dollars to holders of American Depository Shares ("ADS"). A dividend of 1.302 pence per ordinary share (2008: 1.085 pence) and 6.441 US cents per ADS (2008: 6.441 US cents) will be paid on October 8, 2009 to persons whose names appear on the register of members of the Company at the close of business on September 11, 2009.

    Additional Information
    The following additional information is included in this press release:

      
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved 
0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 
Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents

Post Your Comments:

(Date:5/20/2013)... , Collaboration with the ... in treatment of mastitis , ... to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will collaborate ... Service (ARS) to develop and trial products targeting the ...

(Date:5/20/2013)... 20, 2013 Oven Industries Inc. announces ... capabilities. The 5R6-900 benchtop controller has many outstanding user-friendly ... be plugged into the wall as a self-contained temperature ... distinctive detail makes the device unique, as well as ... temperature controller can also be used universally, which allows ...

(Date:5/20/2013)... 2013 Today, at the American Psychiatric Association ... James McGough , M.D., M.S., principal ... Institute for Neuroscience and Human Behavior and ... University of California Los Angeles (UCLA), and director of ... and ADHD at UCLA, presented the results of a ...

(Date:5/20/2013)... SAN DIEGO , May 20, 2013 Dr. ... the field of nucleic acid research, recently launched a ... Zone In with Zon ( zon.trilinkbiotech.com ), focuses on ... posts include interviews with industry thought leaders, discussions of ... publications and more. Dr. Zon (PhD ...

Breaking Biology Technology:Phosphagenics Signs Research Agreement with the Agricultural Research Service 2 New Laboratory Temperature Controller by Oven Industries 2 Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2 Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3 Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4 Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5 Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2

[0] Phosphagenics Signs Research Agreement with the Agricultural Research Service [0] New Laboratory Temperature Controller by Oven Industries [0] Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)[0] Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies

... Investment Conference on... -- HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...

... Calif., Sept. 7 / PRNewswire/ -- Transdel ... announced that Transdel management will present a company overview at ... York City on Monday, September 13, 2010 at 4:05 p.m. ... webcast via the Internet by visiting the Investor Relations section ...

... Exclusive Partnership Agreements for Immunotherapy Tablets in Japan -- ANTONY, France, September 6, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...

Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan

(Date:5/20/2013)... of the planet, inhales carbon dioxide as it exudes oxygen. ... that eventually fall to the ground to decompose or get ... recently people believed much of the rain forest,s carbon floated ... ocean. University of Washington research showed a decade ago that ... open the question of how that was possible, since bark ...

(Date:5/20/2013)... University of Bristol and published online today in the ... how the brain and inner ear developed in dinosaurs. ... Sciences, together with Tom Hbner from the Niederschsische Landesmuseum ... year old dinosaurs. , The two palaeontologists studied different ... a very young (juvenile) individual of approximately three ...

(Date:5/19/2013)... of California, Davis have engineered a strain of photosynthetic ... They report their findings today at the 113th General ... this work, we used synthetic biology approaches to probe ... light energy for growth) cyanobacterial metabolism for the ability ... lead researcher on the study. He is part ...

Breaking Biology News(10 mins):Amazon River exhales virtually all carbon taken up by rain forest 2 Amazon River exhales virtually all carbon taken up by rain forest 3 Fossil brain teaser 2

[0] Amazon River exhales virtually all carbon taken up by rain forest [0] Fossil brain teaser [0] Engineered microbes grow in the dark

... newborn described as a "happy blue baby" because of ... small mark in medical history when one of her ... River mutation. Scientists have identified hundreds of mutations ... protein that carries oxygen in everyone,s red blood cells. ...

... Bethesda, MD "Super bugs," which can cause wide-spread disease ... conventional antibiotics, still have their weaknesses. A team of ... presented in lipid (fatty) mixtures can significantly boost the ... This discovery was published online in The FASEB ...

... has awarded the University of Colorado Boulder a ... of long-term ecological changes in Colorado,s high mountains, ... Awarded to CU-Boulder,s Institute of Arctic and ... and students, including undergraduates, to continue key environmental ...

Cached Biology News:Hematologist discovers, names the 'Toms River' blood mutation in N.J. family 2 Scientists develop a fatty 'kryptonite' to defeat multidrug-resistant 'Super bugs' 2 NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 2 NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 3 NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 4

Hematologist discovers, names the 'Toms River' blood mutation in N.J. family Scientists develop a fatty 'kryptonite' to defeat multidrug-resistant 'Super bugs' NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research

OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...

...

... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...

Biology Products:

OPTIMIX KIT FOR EUKARYOTE from Thermo Scientific Expand High Fidelity PCR System, dNTPack (Not available in US) from Roche Applied Science Human Interferon Gamma Bioassay Services from PBL InterferonSource Human Interferon Beta Bioassay Services from PBL InterferonSource